title: 111In-octreotide scintigraphy in pituitary adenomas.
abstract: This study reports on 111In-octreotide scintigraphy in 20 patients affected with pituitary adenomas, including tracer uptake ratios and in vitro immunohistochemical characterization of the matostatin receptor state. 111In-octreotide uptake was already observed at 4 hours in 7/8 GH-secreting adenomas, in 5/7 non-secreting adenomas and in 1/5 prolactinomas. Concordance between the scan and the histochemical results was observed in all cases. The uptake ratios evaluated at 24 hours ranged from 2.3 to 4.2. The following conclusions were drawn: 1) 111In-octreotide is a suitable tracer to evaluate the somatostatin receptor state of pituitary adenomas; 2) Semi-quantitative measures of tracer uptake can be easily obtained with static planar scanning, but more refined techniques are needed for receptor kinetics evaluation; 3) This nuclear technique is a promising non-invasive tool to identify patients with somatostatin receptor positive pituitary adenomas who might potentially benefit from pre- and/or post-surgery cold octreotide medical treatment.
authors.affiliation: Department of Nuclear Medicine, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Tofani
authors.forename: R
authors.initials: R
authors.lastname: Cucchi
authors.forename: A
authors.initials: A
authors.lastname: Pompili
authors.forename: C
authors.initials: C
authors.lastname: Carapella
authors.forename: M
authors.initials: M
authors.lastname: Crecco
authors.forename: M
authors.initials: M
authors.lastname: Mottolese
authors.forename: C L
authors.initials: CL
authors.lastname: Maini
mesh_terms: D000236:Adenoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D015175:Prolactinoma / Q000000981:diagnostic imaging / Q000378:metabolism; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017481:Receptors, Somatostatin / Q000032:analysis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide